An FDA Reversal on Peptides Could Open the Market to Unsafe Drugs ProPublica FDA's Overreach on Compounded Peptides The Peptide Split: How GLP 1s, Lutathera, Vosoritide, and Peptide Cancer Vaccines Are Quietly Rewriting Medicine While BPC 157, TB 500, MOTS c, and the Wellness Grift Borrow Their Halo The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York